[go: up one dir, main page]

US2179384A - Therapeutic composition and process of making it - Google Patents

Therapeutic composition and process of making it Download PDF

Info

Publication number
US2179384A
US2179384A US135106A US13510637A US2179384A US 2179384 A US2179384 A US 2179384A US 135106 A US135106 A US 135106A US 13510637 A US13510637 A US 13510637A US 2179384 A US2179384 A US 2179384A
Authority
US
United States
Prior art keywords
insulin
protamine
zinc
compositions
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US135106A
Inventor
Scott David Alymer
Fisher Albert Madden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
University of Toronto
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Priority to US135106A priority Critical patent/US2179384A/en
Application granted granted Critical
Publication of US2179384A publication Critical patent/US2179384A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins

Definitions

  • Insulin-containing precipitates in lnsulin"- protarnine compositions will often adhere to the inside of containers in which the compositions are stored.
  • the precipitates commonly form aggregates which cannot readily be adequately disintegrated.
  • the utility of Insulin-protamine compositions in which precipitates either form such aggregates or adhere to the inside of containers is limited, since obviously the precipitates in the compositions should remain completely and homogeneously suspended during withdrawal of doses of the compositions.
  • Insulin-protamine compositions having present in Insulin-protamine compositions as little as half a milligram of zinc (or molecularly equivalent amounts if the other metals are used) per thousandunits oi the Insulin; and desirably, in order to ensure that not less than this quantity of metal be present, we add at least this quantity.
  • any suitable protamine such as salmiridine or scombrine or s'almine, commonly in the range of about 2 to do mg. of protamine per 1000 units of the llnsu1in".
  • zinc in an amount rinsing between about i and about 5 ma. per 1000 units of the Insulin.
  • oi zinc we may add cadmium; and instead oi either zinc or cadmium, we may add nickel or cobalt; but zinc is our first choice, and cadmium our second. Instead of only one of these four metals, we may add two or more.
  • metal of the defined class in the form of chlorides, but we may addmetal in elemental form, or in other forms, such as ace-r tates, oxides or hydroxides. Further, it is possi-.- ble to ensure the presence of adequate metal by conducting some of the production operations in equipment made of or containing the desired. metal or metals.
  • the hydrogen-ion concentrations of the several components and of their mixtures are not of prime importance, but in making such compositions available ior clinical use and in using these, we find it desirable to attain and maintain a reaction which is on the alkaline side of the isoelectric point of the Insulin, desirably a reaction of between pH 6.9 and pHFUi.
  • the desired reaction may be attained by adding an appropriate solution, such as a solution of a suitable buffer (a lid phosphate bufler for example), to one or more of the components or to our otherwise completepreparation.
  • the process 0! producing an "Insulin"- protamine composition, which consists in putting Insulin and protamine together, and ensuring the presence therewith of an amount of metal of the class consisting of zinc, cadmium, nickel, and cobalt sumcient to correspond molecular nowadays to at least half a milligram of zinc per thousand units of the Insulin.
  • composition of matter comprising "Insulin", protamine, and added metal of the. class consisting of zinc, cadmium, nickel, and cobalt.
  • a composition of matter comprising Insulin, protamine, and an amount of metal of the class consisting of zinc, cadmium, nickel, and cobaltsumcient to correspond molecularly to at least half a milligram of zinc per thousand units of the Insulin.
  • composition of matter comprising "Insulinf, protamine, and a quantity of metal of the class consisting of-zinc, cadmium, nickel, and cobalt which per unit of Insulin is at least twice as large molecularly as the quantity of metal present per unit of Insulin" in crystals of Insulin".
  • Acomposition of matter comprising "Insulin”, protamine, and added zinc.
  • a composition of matter comprising Insulin, protamine, and added cadmium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

Patented Na -1, i939 'umrso STATE s PATEN'T orrics' 2,179,384 THERAPEUTIC COMPOSITION AND PROCESS OF MAKIN G IT No Drawing. Application April 5, 1931, Serial No. 135,106. Renewed April 18, 1930 v 10 Qlaims.
it is the object oi our invention to enhance utility of Insulin-protamine compositions.
It has been denmonstrated by Hagedorn and has co-workers that the blood-sugar-lowering action of Insulin" may be prolonged by using protamine with the Insulin. See The Journal of the American Medical Association for January 18, 1036, volume 106, page 1'77.
Experience has shown that all or a part of Insulin"-containing precipitates in lnsulin"- protarnine compositions will often adhere to the inside of containers in which the compositions are stored. Experience, has shown, also, that in lnsulin-protamine compositions the precipitates commonly form aggregates which cannot readily be adequately disintegrated. The utility of Insulin-protamine compositions in which precipitates either form such aggregates or adhere to the inside of containers is limited, since obviously the precipitates in the compositions should remain completely and homogeneously suspended during withdrawal of doses of the compositions.
We have discovered that such limitation oi utility of Insu1in-protamine compositions can be avoided, and in consequence that utility of such compositions can be enhanced, by having present in the compositions an adequate amount of metal of the class consisting of zinc, cadmium, nickel, and cobalt. Also, we have discovered that by the presence of this amount of metal of the class defined the period of utility of Insulin"- protamine compositions is greatly lengthened. Moreover, we find that by the presence of this amount of either zinc or cadmium in Insulinprotamine compositions the prolonged bloodsugar-lowering action of the compositions is eittended. We here assert no theory as to the nature of the actions of the metal present, or as to whether or not there is any chemical combination between the metal and either or both of the Insulin and the protamine components.
According to our invention, in preparing Insulin-protamine compositions we ensure the presence in the compositions of an amount of zinc, cadmium, nickel, and/or cobalt, per unit of Insulin", that is larger than the amount of such metal present per' unit of Insulin" in ordinary preparations of Insulin or in Insulin-protamine compositions as made prior to our discovery,
and that is at least twice as large, molecularly, as
the amount of such metal present per unit of Insulln" in crystals of "Insulln. ["Insulin crystallized with zinc contains about 0.52% of zinc, Insulin" crystallized. with cadmium contains about 0.77% of cadmium, Insulin crystallized with nickel contains about 0.41% of nickel, and Insulin crystallized with cobalt contains about 0.44% of cobalt, in terms or dry weight of the crystals] Beneficial results are obtainable by. having present in Insulin-protamine compositions as little as half a milligram of zinc (or molecularly equivalent amounts if the other metals are used) per thousandunits oi the Insulin; and desirably, in order to ensure that not less than this quantity of metal be present, we add at least this quantity. We may add any larger quantity of metal provided only that the quantity added be not so large as to induce untoward reactions, such as undue pain from injections. We have obtained satisfactory results from adding 20 me. of zinc (and also'from adding molecularly equivalent quantities of the other metals) per 1000 units of the insulin. Most desirably we ensure the presence oi a total of about 2 mg. of zinc per 1000 units oi the lnsu1in".
Illustrations oi our invention are as follows:
In any desired way we make a preparation of Insulin and protamine-as by adding to a solution of Insulin any suitable protamine, such as salmiridine or scombrine or s'almine, commonly in the range of about 2 to do mg. of protamine per 1000 units of the llnsu1in". During or following the operations of malrlng this preparation, we add zinc in an amount rinsing between about i and about 5 ma. per 1000 units of the Insulin. Instead oi zinc, we may add cadmium; and instead oi either zinc or cadmium, we may add nickel or cobalt; but zinc is our first choice, and cadmium our second. Instead of only one of these four metals, we may add two or more. Preferably we add metal of the defined class in the form of chlorides, but we may addmetal in elemental form, or in other forms, such as ace-r tates, oxides or hydroxides. Further, it is possi-.- ble to ensure the presence of suficient metal by conducting some of the production operations in equipment made of or containing the desired. metal or metals.
In preparing our new compositions the hydrogen-ion concentrations of the several components and of their mixtures are not of prime importance, but in making such compositions available ior clinical use and in using these, we find it desirable to attain and maintain a reaction which is on the alkaline side of the isoelectric point of the Insulin, desirably a reaction of between pH 6.9 and pHFUi. The desired reaction may be attained by adding an appropriate solution, such as a solution of a suitable buffer (a lid phosphate bufler for example), to one or more of the components or to our otherwise completepreparation.
We claim as our invention:
1. The process 0! producing an "Insulin"- protamine composition, which consists in putting Insulin and protamine together, and ensuring the presence therewith of an amount of metal of the class consisting of zinc, cadmium, nickel, and cobalt sumcient to correspond molecular?! to at least half a milligram of zinc per thousand units of the Insulin.
2. The process of producing an Insulin"- protamine composition, which consists in adding a protamine to Insulin, and also adding metal of the class consisting of zinc, cadmium, nickel, and cobalt.
3. The process of producing an Insuiin"- protamine composition, which consists in adding a protamine to Insulin", and also adding metal of the class consisting of zinc, cadmium, nickel, and cobalt in suflicient amount to make the total quantity of such metal present per unit of Insulin" at least twice as large molecularly as the quantity of metal present per unit of Insulin'' in crystals of Insulin.
4. The process of producing an Insulin"- protamine composition, which consists in adding to Insulin" a protamine and zinc.
5. The process of producing an Insulin protamine composition, which consists in adding to Insulin" a protamine and cadmium.
6. A composition of matter, comprising "Insulin", protamine, and added metal of the. class consisting of zinc, cadmium, nickel, and cobalt.
7. A composition of matter, comprising Insulin, protamine, and an amount of metal of the class consisting of zinc, cadmium, nickel, and cobaltsumcient to correspond molecularly to at least half a milligram of zinc per thousand units of the Insulin.
8. A composition of matter, comprising "Insulinf, protamine, and a quantity of metal of the class consisting of-zinc, cadmium, nickel, and cobalt which per unit of Insulin is at least twice as large molecularly as the quantity of metal present per unit of Insulin" in crystals of Insulin".
9. Acomposition of matter, comprising "Insulin", protamine, and added zinc.
10. A composition of matter, comprising Insulin, protamine, and added cadmium.
DAVID ALYMER SCOTT. ALBERT MADDEN FISHER.
US135106A 1937-04-05 1937-04-05 Therapeutic composition and process of making it Expired - Lifetime US2179384A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US135106A US2179384A (en) 1937-04-05 1937-04-05 Therapeutic composition and process of making it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US135106A US2179384A (en) 1937-04-05 1937-04-05 Therapeutic composition and process of making it

Publications (1)

Publication Number Publication Date
US2179384A true US2179384A (en) 1939-11-07

Family

ID=22466579

Family Applications (1)

Application Number Title Priority Date Filing Date
US135106A Expired - Lifetime US2179384A (en) 1937-04-05 1937-04-05 Therapeutic composition and process of making it

Country Status (1)

Country Link
US (1) US2179384A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2734016A (en) * 1956-02-07 Protamine zinc adrenocorticotrophin
DE960492C (en) * 1952-02-29 1957-03-21 Hoechst Ag Process for the production of crystallized islet hormone preparations
US2787575A (en) * 1950-11-22 1957-04-02 Organon Zinc-glycine-insulin composition and production thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US5070186A (en) * 1986-10-20 1991-12-03 Novo Industri A/S Magnesium containing insulin solution
US5382574A (en) * 1989-12-21 1995-01-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734016A (en) * 1956-02-07 Protamine zinc adrenocorticotrophin
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2787575A (en) * 1950-11-22 1957-04-02 Organon Zinc-glycine-insulin composition and production thereof
DE960492C (en) * 1952-02-29 1957-03-21 Hoechst Ag Process for the production of crystallized islet hormone preparations
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US5070186A (en) * 1986-10-20 1991-12-03 Novo Industri A/S Magnesium containing insulin solution
US5382574A (en) * 1989-12-21 1995-01-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide

Similar Documents

Publication Publication Date Title
US2820740A (en) Therapeutic preparations of iron
US2492085A (en) Aluminum chlorohydrate astringent
US2179384A (en) Therapeutic composition and process of making it
SOUTHREN et al. Testosterone and androstenedione metabolism in the polycystic ovary syndrome: Studies of the percentage binding of testosterone in plasma
US3450814A (en) Ophthalmic compositions containing alginic acid salts of pilocarpine,atropine and physostigmine
US3148970A (en) Gelled ammonia solution and method for producing same
US2253389A (en) Jelly and manufacture thereof
US2689203A (en) Preparation of stabilized catalase
GB1422193A (en) Pharmaceutical compositions
US1961576A (en) Stable calcium hypochlorite composition
US1995663A (en) Cosmetical preparation
US3584121A (en) Quick-acting,stable,neutral solution of bovine insulin and process for the production thereof
US2022729A (en) Stable colloidal solution of iodine
US2250474A (en) Sterilization process
US2281612A (en) Iodine compound and method for producting the same
US2071043A (en) Oral preparation
US2390746A (en) Soluble sulphur preparations
US2317297A (en) Dentifrice
GB224891A (en) Improved dentifrice material
GB1185685A (en) Method of Making Pharmaceutical Compositions
US2004891A (en) Anaesthetic composition
US2326275A (en) Process for the preparation of catalysts for hydrogenation
US2047275A (en) Therapeutic preparations
US2556959A (en) Dentifrice and method of preparing same
US2751327A (en) Preparation of hair treating compositions in solid form